Expand All Collapse All
IID-11.3 Increase the vaccination coverage level of 1 dose meningococcal conjugate vaccine for adolescents by age 13 to 15 years
About the Data: National
Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.
Number of persons aged 13 to 15 years receiving at least 1 dose of meningococcal conjugate vaccine
Number of persons aged 13 to 15 years
From the 2013 National Immunization Survey-Teen Provider-Immunization History Questionnaire:
[NUMERATOR:]
Specify month, day, and year that each vaccine was given, either by the office or another provider, and type of vaccine, as documented in the records.
The National Immunization Survey-Teen (NIS-Teen) collects vaccination information for adolescents aged 13–17 years in the 50 states, the District of Columbia, selected areas, and the U.S. Virgin Islands, using a random-digit-dialed sample of landline and, starting in 2011, cellular telephone numbers. Parent/guardian respondents provide vaccination and sociodemographic information on adolescents in their care. After the parent/guardian grants permission to contact their child's vaccination provider, a questionnaire is mailed to that provider to obtain a vaccination history from the medical record. Data for this measure are restricted to adolescents aged 13–15 and weighted to represent the population of adolescents age 13–15, with adjustments for households with multiple telephone lines and mixed telephone use (landline and cellular), household nonresponse, and exclusion of households without telephone service.
In 2005, the Advisory Committee on Immunization Practices (ACIP) recommended the routine vaccination of adolescents aged 11–12 years at the preadolescent health care visit and for adolescents before high school entry. In 2008, the ACIP expanded its recommendations to the routine administration of meningococcal vaccine at 11–12 years of age and 13–18 years of age if not previously vaccinated. In 2011, the ACIP recommended that a single dose of vaccine be administered at age 11 or 12 years, with a booster dose at age 16 years for persons who receive the first dose before age 16 years.
This measure tracks the proportion of adolescents aged 13–15 years receiving at least 1 of the meningococcal conjugate vaccine (MenACWY) and meningococcal-unknown type vaccine.
About the Data: State
Description of the data source, numerator, denominator, survey questions, and other relevant details about the state-level data.
Number of persons aged 13 to 15 years receiving at least 1 dose of meningococcal conjugate vaccine
Number of persons aged 13 to 15 years
From the 2013 National Immunization Survey-Teen Provider-Immunization History Questionnaire:
[NUMERATOR:]
Specify month, day, and year that each vaccine was given, either by the office or another provider, and type of vaccine, as documented in the records.
The National Immunization Survey-Teen (NIS-Teen) collects vaccination information for adolescents aged 13–17 years in the 50 states, the District of Columbia, selected areas, and the U.S. Virgin Islands, using a random-digit-dialed sample of landline and, starting in 2011, cellular telephone numbers. Parent/guardian respondents provide vaccination and sociodemographic information on adolescents in their care. After the parent/guardian grants permission to contact their child's vaccination provider, a questionnaire is mailed to that provider to obtain a vaccination history from the medical record. Data for this measure are restricted to adolescents aged 13–15 and weighted to represent the population of adolescents age 13–15, with adjustments for households with multiple telephone lines and mixed telephone use (landline and cellular), household nonresponse, and exclusion of households without telephone service.
In 2005, the Advisory Committee on Immunization Practices (ACIP) recommended the routine vaccination of adolescents aged 11–12 years at the preadolescent health care visit and for adolescents before high school entry. In 2008, the ACIP expanded its recommendations to the routine administration of meningococcal vaccine at 11–12 years of age and 13–18 years of age if not previously vaccinated. In 2011, the ACIP recommended that a single dose of vaccine be administered at age 11 or 12 years, with a booster dose at age 16 years for persons who receive the first dose before age 16 years.
This measure tracks the proportion of adolescents aged 13–15 years receiving at least 1 of the meningococcal conjugate vaccine (MenACWY) and meningococcal-unknown type vaccine.
Revision History
Any change to the objective text, baseline, target, target-setting method or data source since the Healthy People 2020 launch.
References
Additional resources about the objective
- Datasets for the National Immunization Survey - Teen [online]. Atlanta (GA): National Center for Immunization and Respiratory Diseases. c2013 – [cited 2013 June 6].